MedPath

ASAN FOUNDATION

ASAN FOUNDATION logo
🇰🇷South Korea
Ownership
Private
Established
1989-06-23
Employees
501
Market Cap
-
Website
https://ails.amc.seoul.kr

Daewoong Pharmaceutical Advances Phase 2 Trial of Novel IPF Drug Bersiporocin with Diverse Patient Population

Daewoong Pharmaceutical presented interim Phase 2 results for Bersiporocin (DWN12088), a first-in-class oral antifibrotic drug targeting idiopathic pulmonary fibrosis, at the 2025 American Thoracic Society International Conference.

Huonslab Completes Enrollment in Phase 1 Trial for Recombinant Hyaluronidase, Eyes 2025 Regulatory Filing

Huonslab has completed patient enrollment in its pivotal Phase 1 clinical trial of HLB3-002 (Hydizyme™), a recombinant human hyaluronidase, with 243 healthy volunteers across four leading South Korean medical centers.

Early Hepatitis B Treatment with Vemlidy Shows Promise in Preventing Liver Cancer

Interim analysis of the ATTENTION trial suggests early treatment with Vemlidy (tenofovir alafenamide) significantly reduces liver-related events in hepatitis B patients.

ROTEM-Guided TXA Administration vs. Preemptive TXA for Bleeding in Cardiovascular Surgery: A Randomized Trial

A multi-center, double-blind, randomized trial is underway to compare ROTEM-guided tranexamic acid (TXA) administration with preemptive TXA in cardiovascular surgery patients.

Fecal Microbiota Transplants Show Promise in Overcoming Immunotherapy Resistance in GI Cancers

A South Korean study suggests fecal microbiota transplants (FMTs) may enhance immunotherapy efficacy in gastrointestinal (GI) cancer patients resistant to anti-PD-1 drugs.

Flexible Antiplatelet Management Safe After Drug-Eluting Stent Implantation

A recent trial suggests that discontinuing antiplatelet therapy around non-cardiac surgery is non-inferior to continuing aspirin monotherapy for patients with prior drug-eluting stent (DES) implantation.

© Copyright 2025. All Rights Reserved by MedPath